Oral Coenzyme Q10 Supplementation In Patients With Migraine: Effects On Clinical Features And Inflammatory Markers
Notes for this study:
||(ng/L). Mean and SD. Placebo: before 54.93 ± 33.53, after 58.29 ± 35.67. Intervention: before 76.87 ± 53.94, after 66.77 ± 42.81.
|Number of Subjects
In a randomized, double-blind, placebo-controlled trial, 45 premenopausal women with episodic migraine were allocated to take 400 mg of coq10 daily or placebo for 3 months.
Migraine frequency, severity, and duration were all reduced significantly more than placebo. Calcitonin gene-related peptide and tumor necrosis factor were reduced significantly more in the coq10 group, while IL-6 was reduced nonsignificantly more, and IL-10 increased nonsignificantly more.